Apimeds Pharmaceuticals US, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | $-6.0M | $-1.4M | $-777.7K |
| Depreciation & Amortization | — | — | — |
| Depreciation | $5.7K | — | — |
| Amortization | — | — | — |
| Stock-Based Compensation | $1.6M | — | $70.0K |
| Net Cash from Operating Activities | $-8.9M | $-733.5K | $-627.8K |
| Investing Activities | |||
| Capital Expenditures | $57.3K | — | — |
| Business Acquisitions | $-15.3K | — | — |
| Net Cash from Investing Activities | $-10.1M | — | — |
| Financing Activities | |||
| Dividends Paid | — | — | — |
| Stock Repurchases | — | — | — |
| Net Cash from Financing Activities | $20.6M | $326.5K | $1.0M |
| Net Change in Cash | — | — | — |
| Free Cash Flow | $-9.0M | — | — |